Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -25.47% is 11% above its 2-year average of -28.50%, near the high end of its 2-year range (-56.20%–-19.78%).
As of the fiscal period ended Tuesday, June 30, 2026. 2.10% below its 12-month average of -24.94%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -25.47%.
RETURN ON EQUITY (ROE)
-25.47%
RETURN ON EQUITY (ROE) AVG TTM
-24.94%
RETURN ON EQUITY (ROE) AVG 3Y
N/A
RETURN ON EQUITY (ROE) AVG 5Y
N/A
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-2.10%
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-40.75%
median of 682 covered companies
CURRENT VS SECTOR MEDIAN
+37.52%
vs the sector median at left
MBX Biosciences, Inc. Common Stock
Market Cap
$2.67B
Return on Equity (ROE)
-25.47%
TTM Avg
-24.94%
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$2.67B
Return on Equity (ROE)
95.64%
TTM Avg
115.72%
3Y Avg
76.74%
5Y Avg
3213.80%
Market Cap
$2.68B
Return on Equity (ROE)
-56.91%
TTM Avg
-24.13%
3Y Avg
-9.83%
5Y Avg
-11.19%
Market Cap
$2.65B
Return on Equity (ROE)
-0.38%
TTM Avg
-26.55%
3Y Avg
-13.53%
5Y Avg
-6.91%
Market Cap
$2.73B
Return on Equity (ROE)
-361.91%
TTM Avg
-763.19%
3Y Avg
-396.22%
5Y Avg
-320.76%
Market Cap
$2.59B
Return on Equity (ROE)
-8.00%
TTM Avg
-28.91%
3Y Avg
-27.68%
5Y Avg
-39.13%
Market Cap
$2.58B
Return on Equity (ROE)
0.00%
TTM Avg
2.68%
3Y Avg
1.94%
5Y Avg
-2.51%
Market Cap
$2.58B
Return on Equity (ROE)
-41.10%
TTM Avg
-30.86%
3Y Avg
-32.08%
5Y Avg
-34.60%
Market Cap
$2.79B
Return on Equity (ROE)
2.04%
TTM Avg
-6.01%
3Y Avg
-7.18%
5Y Avg
-5.00%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| MBX Biosciences, Inc. Common Stock (MBX) | $2.67B | -25.47% | -24.94% | N/A | N/A |
| Aveanna Healthcare Holdings Inc. (AVAH)vs › | $2.67B | 95.64% | 115.72% | 76.74% | 3213.80% |
| Acadia Healthcare Company, Inc. (ACHC)vs › | $2.68B | -56.91% | -24.13% | -9.83% | -11.19% |
| Neogen Corporation (NEOG)vs › | $2.65B | -0.38% | -26.55% | -13.53% | -6.91% |
| Precigen, Inc. (PGEN)vs › | $2.73B | -361.91% | -763.19% | -396.22% | -320.76% |
| Beam Therapeutics Inc. (BEAM)vs › | $2.59B | -8.00% | -28.91% | -27.68% | -39.13% |
| Privia Health Group, Inc. (PRVA)vs › | $2.58B | 0.00% | 2.68% | 1.94% | -2.51% |
| NewAmsterdam Pharma Company N.V. (NAMS)vs › | $2.58B | -41.10% | -30.86% | -32.08% | -34.60% |
| AtriCure, Inc. (ATRC)vs › | $2.79B | 2.04% | -6.01% | -7.18% | -5.00% |
| TransMedics Group, Inc. (TMDX)vs › | $2.81B | 29.28% | 27.86% | 4.54% | -12.45% |
ROE
-25.5%
ROA
-23.9%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -25.47% |
| 2026-03-31 | -19.78% |
| 2025-12-31 | -23.56% |
| 2025-09-30 | -20.77% |
| 2025-06-30 | -35.13% |
| 2025-03-31 | -31.21% |
| 2024-12-31 | -24.05% |
| 2024-09-30 | -20.33% |
| 2024-03-31 | -56.20% |
